Hurley Capital LLC Invests $89,000 in McKesson Co. (NYSE:MCK)

by · The Cerbat Gem

Hurley Capital LLC bought a new stake in shares of McKesson Co. (NYSE:MCKFree Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 153 shares of the company’s stock, valued at approximately $89,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MCK. Rhenman & Partners Asset Management AB grew its holdings in McKesson by 13.3% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 34,117 shares of the company’s stock valued at $19,444,000 after buying an additional 4,000 shares in the last quarter. Resona Asset Management Co. Ltd. purchased a new stake in McKesson in the fourth quarter worth $29,898,000. Islay Capital Management LLC raised its stake in shares of McKesson by 4,992.0% during the fourth quarter. Islay Capital Management LLC now owns 1,273 shares of the company’s stock valued at $725,000 after acquiring an additional 1,248 shares in the last quarter. Lynwood Price Capital Management LP bought a new stake in shares of McKesson in the fourth quarter valued at about $7,181,000. Finally, First Western Trust Bank lifted its stake in McKesson by 2.0% in the fourth quarter. First Western Trust Bank now owns 931 shares of the company’s stock worth $531,000 after acquiring an additional 18 shares during the period. 85.07% of the stock is owned by hedge funds and other institutional investors.

McKesson Stock Performance

MCK stock opened at $682.41 on Friday. The stock’s fifty day moving average is $633.37 and its two-hundred day moving average is $584.91. The stock has a market capitalization of $85.52 billion, a price-to-earnings ratio of 31.25, a PEG ratio of 1.29 and a beta of 0.49. McKesson Co. has a 1 year low of $464.42 and a 1 year high of $728.32.

McKesson (NYSE:MCKGet Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. As a group, analysts predict that McKesson Co. will post 32.77 EPS for the current fiscal year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Monday, March 3rd were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, March 3rd. This represents a $2.84 dividend on an annualized basis and a yield of 0.42%. McKesson’s payout ratio is 13.00%.

Analyst Ratings Changes

A number of research analysts have recently issued reports on MCK shares. Citigroup cut their price target on McKesson from $713.00 to $677.00 and set a “buy” rating on the stock in a report on Friday, January 10th. StockNews.com lowered shares of McKesson from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Morgan Stanley lifted their target price on shares of McKesson from $642.00 to $745.00 and gave the company an “overweight” rating in a report on Wednesday. Evercore ISI increased their price target on McKesson from $650.00 to $675.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Finally, Wells Fargo & Company boosted their price objective on McKesson from $641.00 to $691.00 and gave the stock an “equal weight” rating in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, McKesson presently has a consensus rating of “Moderate Buy” and a consensus target price of $661.00.

View Our Latest Stock Analysis on McKesson

Insider Activity

In related news, CEO Brian S. Tyler sold 8,961 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total value of $5,358,588.39. Following the completion of the transaction, the chief executive officer now directly owns 60,664 shares of the company’s stock, valued at $36,276,465.36. This trade represents a 12.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Leann B. Smith sold 188 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total value of $114,602.92. Following the completion of the transaction, the executive vice president now directly owns 1,051 shares in the company, valued at $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,110 shares of company stock worth $10,855,706. 0.11% of the stock is owned by corporate insiders.

McKesson Company Profile

(Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

See Also

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCKFree Report).